The treatment, bamlanivimab and etesevimab administered together, was granted FDA emergency use authorization in February.
Eli Lilly and the FDA stipulated that the antibody cocktail is authorized as a COVID-19 prophylaxis only for individuals who have been exposed to the virus. They also said the treatment is not a substitute for a COVID-19 vaccine.
Eli Lilly’s antibody cocktail is the second to be granted emergency use authorization for post-exposure COVID-19 prophylaxis, as the FDA revised the emergency use authorization for Regeneron’s COVID-19 antibody cocktail, a combination of of casirivimab and imdevimab, in July.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.